Testing KQB368 for Advanced Solid Cancers with KRAS Mutations
Part of Cancer, Digestive system, Lungs & breathing, Women’s health & pregnancy clinical trials.
This study tests a new drug called KQB368 for advanced solid cancers that have a specific genetic change (KRAS G12C or G12S mutation). The drug is designed to target this mutation and may help slow or shrink tumors in patients who don't have other curative treatment options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your cancer must be confirmed by biopsy or pathology report (histologically confirmed solid tumor)
- Your cancer must have a KRAS G12C or KRAS G12S genetic mutation
- Your cancer is advanced, meaning it cannot be surgically removed or has spread to other parts of your body
- There are no other standard treatments that could cure your cancer
- Your organs (liver, kidneys, heart, etc.) function well enough to tolerate the study drug
- Your cancer can be measured on imaging scans, and you can swallow pills without stomach or digestive problems that would prevent the drug from being absorbed
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, QLC1101, for people with advanced solid tumors that have a specific genetic change called KRAS G12D. It may be an option if you have tried other treatments or cannot take them.
This early-stage trial tests BLU-924, a new drug designed to target cancer cells with specific KRAS mutations (a common genetic change in pancreatic, lung, and colon cancers). The study aims to find the right dose and see how well it works in patients whose cancers have progressed despite standard treatments.
This Phase 1/2a trial tests two investigational pills (JAB-21822 and JAB-3312) in people with advanced solid cancers that have a KRAS G12C mutation. It’s for cases where standard treatments have failed or aren’t suitable, to see if the drugs can shrink tumors and improve outcomes.
This trial tests a new targeted drug, HS-10529, for people with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to see if the drug can shrink tumors or slow their growth in patients who have already tried standard therapies.
This trial tests a new drug called KQB365, alone or with other drugs, for people with advanced solid tumors that have a specific KRAS mutation (G12C or G12S). It aims to see if the treatment is safe and effective.
This trial tests a new drug called KQB548 for people with certain advanced cancers (pancreatic, colorectal, or lung) that have a specific genetic change called KRAS G12D. It's for those whose cancer has continued to grow despite previous treatments.
Hear when a new Colorectal Cancer (CRC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.